Monoclonal antibodies

683 views
655 views

Published on

Published in: Business, News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
683
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
16
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Monoclonal antibodies

  1. 1. Monoclonal Antibodies: 2011IntroductionAcross the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast tobe the strongest performing molecule type, delivering a forecast six year compound annual growth rateof 8.2% over 2010-16, outpacing the growth rates of small molecules, therapeutic proteins and vaccines.Features and benefits Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target. The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.Buy Now: 2011 Monoclonal Antibodies marketHighlights While Datamonitor believes biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry. Your key questions answered Assess the outlook for the monoclonal antibodies sector through to 2016 Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universeTable Of ContentsABOUT THIS SECTOR REPORTPharmaVitae Explorer databaseChapter structureMAb technology overviewMarket analysis updateData sourcingEXECUTIVE SUMMARYKey findingsIntroduction to the PharmaVitae company universeThe prescription pharmaceutical market performance, 2010–16Prescription pharmaceutical market performance, 2010–16
  2. 2. Biologics-driven growth, 2010–16Introduction to molecule type analysisPrescription pharmaceutical market, by molecule type, 2004–16The monoclonal antibody market dynamicsKey MAb product performance, 2010–16Key MAb company performance, 2010–16MAb market pipeline snapshotTherapy area pipeline analysisCompany pipeline analysisMAB TECHNOLOGY OVERVIEWKey findingsIntroductionThe immune systemB lymphocytes and antibodiesAntibody structureHybridoma technique: the production of MAbsMonoclonal antibodies as therapeutic agentsTargetsProduction of MAbsMode of actionEvolution of MAbsLimitations associated with immunizationMurineChimeric and humanized antibodiesConjugatedEmerging technologiesSystematic naming of MAbsThe MAb timeline: technology evolutionMARKET ANALYSIS UPDATEKey findingsIntroductionThe MAb market: overview of the fastest growing sector across the pharmaceutical industryKey global MAb products over 2004–16MAb market product analysis over 2004–16Historical product analysis over 2004–10Forecast product analysis over 2010–16MAb market company analysis over 2004–16Historical company analysis over 2004–10Forecast company analysis over 2010–16MAb market therapy area analysis over 2004–16Historical therapy area analysis over 2004–10Forecast therapy area analysis over 2010–16MAb market technology analysis over 2004–16Historical technology analysis over 2004–10Forecast technology analysis over 2010–16MAb market target analysis over 2004–16
  3. 3. Historical target analysis over 2004–10Forecast target analysis over 2010–16APPENDIXMonoclonal antibody development pipelineReferencesDatamonitor reportsAbbreviationsExchange ratesLIST OF TABLESTable: PharmaVitae company coverage, by peer setTable: Molecule type definitionsTable: General characteristics of small molecule drugs versus biologicsTable: Prescription pharmaceutical sales, by molecule type ($m), 2010–16Table: Key MAb product performance, 2010–16Table: Key MAb company performance, 2010–16Table: Number of MAb pipeline candidates, by therapy area, Phase I to registrationTable: Number of pipeline candidates, by company, Phase I to registrationTable: Overview of a selection of marketed MAbs: technology type and immunogenicityTable: Infix nomenclature for MAbsTable: Global top five MAb sales ($m), 2004, 2010, and 2016Table: Annual revenues of the Big 5, 2010 and 2016Table: Historical MAb product sales ($m), 2004–10Table: Forecast product sales ($m), 2010–16Table: Historical MAb sales, by company ($m), 2004–10Table: Forecast MAb sales, by company ($m), 2010–16Table: Historical MAb sales, by therapy area ($m), 2004–10Table: Forecast MAb sales, by therapy area ($m), 2010–16Table: Historical MAb sales, by technology ($m), 2004–10Table: Forecast MAb sales, by technology ($m), 2010–16Table: Historical MAb sales, by target ($m), 2004–10Table: Forecast MAb sales, by target ($m), 2010–16Table: MAb pipeline overview, 2011Table: Exchange rates, 2011LIST OF FIGURESFigure: The PharmaVitae ExplorerFigure: The total pharmaceutical market outlook, sales ($m) and year-on-year growth rate (%), 2004–16Figure: Total sales of the prescription pharmaceutical market ($m), 2004–16Figure: Total sales growth of the prescription pharmaceutical market, by molecule type ($bn), 2004–16Figure: CAGR of PharmaVitae universe, by molecule type, 2004–16Figure: Total sales of the MAb market ($m and %), 2004–16Figure: Proportion of the "Big 5" in the MAb sector ($%), 2004–16Figure: MAb sector market share, by company, 2004–16Figure: Number of MAb pipeline candidates, by therapy area, Phase I to registrationFigure: Number of MAb pipeline candidates, by company and therapy area, Phase I to registrationFigure: The structure of an antibody
  4. 4. Figure: Types of antibodiesFigure: Immunogenicity rangesFigure: Schematic illustration of antibody fragmentsFigure: MAb timeline – technology shiftFigure: Total sales of the MAb market ($m and %), 2004–16Figure: MAb product sales ($m), 2004–16Figure: Growth driver/resistor products of historical revenue performance ($m), 2004–10Figure: Growth driver/resistor products of forecast revenue performance ($m), 2010–16Figure: MAb sales, by company ($m), 2004–16Figure: Growth driver/resistor companies of historical revenue performance ($m), 2004–10Figure: Growth driver/resistor companies of forecast revenue performance ($m), 2010–16Figure: MAb sales, by therapy area ($m), 2004–16Figure: Growth driver/resistor therapy areas of forecast revenue performance ($m), 2010–16Figure: MAb sales, by technology ($m), 2004–16Figure: Growth driver/resistor technologies of forecast revenue performance ($m), 2010–16Figure: MAb sales, by target ($m), 2004–16Figure: Growth driver/resistor targets of forecast revenue performance ($m), 2010–16Latest Research Reports:  Biogas Upgrading: Technologies and Global Markets (Focus on Europe)  U.S. Market for Dental Hygiene and Oral Care 2011  U.S. Market for Orthopedic Soft Tissue Repair and Sports Medicine 2011  European Markets for Women’s Health Devices 2011  European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive)About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depth marketresearch studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support toour customers. Get in touch with us for your needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsContact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comVisit our Market Research Blog

×